Prime Therapeutics launches new MedsYourWay™ offering, now giving Blue Plan members home delivery prescription option using Amazon Pharmacy
October 6, 2021
EAGAN, Minn. – Prime Therapeutics LLC, a leading pharmacy benefit manager, announces its new MedsYourWay™ offering, designed to deliver breakthrough consumer shopping experiences for members of participating Blue Plans.
The first offering through MedsYourWay includes a new home delivery option using Amazon Pharmacy. Blue Plans will now have an additional home delivery option that they can choose to offer their members and clients. This new home delivery option with Amazon Pharmacy includes notable customer benefits, including simplified sign-up, real-time medication price displays and an integrated MedsYourWay prescription discount card administered by Inside Rx¹. Covered purchases with the MedsYourWay prescription discount card accrue toward a member’s out of pocket maximums and deductibles.
“MedsYourWay will challenge the traditional thinking in the PBM industry,” said Jarrod Henshaw, senior vice president, chief innovation and supply chain officer for Prime Therapeutics. “This umbrella offering is a reflection of what makes Prime Therapeutics so unique in the industry – true channel independence and an unbiased approach in identifying the best consumer solutions that allow our Blue Plan members to easily access low-cost medications. The first MedsYourWay offering for home delivery using Amazon Pharmacy is an excellent representation of this basic, but critical tenet of how we do business with our Blue Plan partners. We look forward to working with Amazon Pharmacy on the launch of the new offering.”
Over the coming months, additional breakthrough consumer shopping experiences will be launched by Prime Therapeutics under the MedsYourWay offering.
- Inside Rx, a subsidiary of Evernorth.
October 18, 2021
Cancer patients, caregivers benefit with integrated clinic-to-pharmacy care through Prime Therapeutics’ IntegratedRx™ – Oncology
EAGAN, Minn. – Prime Therapeutics, a leading pharmacy benefit manager (PBM) serving more…
October 14, 2021
In first of its kind study, Prime Therapeutics explores paroxysmal nocturnal hemoglobinuria (PNH) C5 inhibitor treatment rates
EAGAN, Minn. – Leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) used its…
September 29, 2021
Prime Therapeutics and Pear Therapeutics announce first comprehensive value-based agreement for prescription digital therapeutics reSET® and reSET-O® for the treatment of substance and opioid use disorders
BOSTON and EAGAN, Minn. – More than 20 million Americans struggle with drug…